These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16764024)

  • 1. [Protective effect of rosiglitazone on myocardium in diabetic cardiomyopathy of rats].
    Lu YL; Wang YN; Zhang L; Zhu L; Zhao JB; Wu H; Wang NC; Wang XF; Yu DL
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 May; 35(3):245-50. PubMed ID: 16764024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosiglitazone (PPAR γ agonist) on the myocardium in non-hypertensive diabetic rats (PPAR γ).
    Abou Daya K; Abu Daya H; Nasser Eddine M; Nahhas G; Nuwayri-Salti N
    J Diabetes; 2015 Jan; 7(1):85-94. PubMed ID: 24548695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy.
    Sun D; Shen M; Li J; Li W; Zhang Y; Zhao L; Zhang Z; Yuan Y; Wang H; Cao F
    Cardiovasc Diabetol; 2011 Jan; 10():4. PubMed ID: 21232147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.
    Baraka A; AbdelGawad H
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):175-81. PubMed ID: 20133494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone, a peroxisome proliferator-activated receptor γ stimulant, abrogates diabetes-evoked hypertension by rectifying abnormalities in vascular reactivity.
    El-Bassossy HM; Abo-Warda SM; Fahmy A
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):643-9. PubMed ID: 22594672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats.
    Guo Z; Qin Z; Zhang R; Li J; Yin Y
    Eur J Pharmacol; 2012 Jun; 685(1-3):116-25. PubMed ID: 22542658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
    Ihm SH; Chang K; Kim HY; Baek SH; Youn HJ; Seung KB; Kim JH
    Basic Res Cardiol; 2010 May; 105(3):399-407. PubMed ID: 19902320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury.
    Khandoudi N; Delerive P; Berrebi-Bertrand I; Buckingham RE; Staels B; Bril A
    Diabetes; 2002 May; 51(5):1507-14. PubMed ID: 11978649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Protective effect of rosiglitazone sodium on islet beta-cell of STZ induced diabetic rats through JNK pathway].
    Liu GY; An ZM
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):430-4. PubMed ID: 19626998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.
    Wang S; Jiang JL; Hu CP; Zhang XJ; Yang DL; Li YJ
    Diabetes Metab Res Rev; 2007 Feb; 23(2):157-64. PubMed ID: 16770837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of rosiglitazone with insulin combination therapy on oxidative stress and lipid profile in left ventricular muscles of diabetic rats.
    Kavak S; Ayaz L; Emre M
    Exp Diabetes Res; 2012; 2012():905683. PubMed ID: 22829806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rosiglitazone is effective to improve renal damage in type-1-like diabetic rats.
    Huang KC; Cherng YG; Chen LJ; Hsu CT; Cheng JT
    Horm Metab Res; 2014 Apr; 46(4):240-4. PubMed ID: 24136780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of peroxisome proliferator-activated receptor gamma and its ligand on blood-retinal barrier in a streptozotocin-induced diabetic model.
    Muranaka K; Yanagi Y; Tamaki Y; Usui T; Kubota N; Iriyama A; Terauchi Y; Kadowaki T; Araie M
    Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4547-52. PubMed ID: 17003451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Streptozotocin induced cardiomyopathy in diabetic rats.
    Zhu XX; Zhou XP; Zhong XL; Zhong CS; Yu YF
    Chin Med J (Engl); 1993 Jun; 106(6):463-6. PubMed ID: 8222899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renoprotective effect of rosiglitazone through the suppression of renal intercellular adhesion molecule-1 expression in streptozotocin-induced diabetic rats.
    Qian Y; Li S; Ye S; Chen Y; Zhai Z; Chen K; Yang G
    J Endocrinol Invest; 2008 Dec; 31(12):1069-74. PubMed ID: 19246972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroprotective effects of the insulin sensitizers rosiglitazone and metformin against indomethacin-induced gastric ulcers in Type 2 diabetic rats.
    Morsy MA; Ashour OM; Fouad AA; Abdel-Gaber SA
    Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):173-7. PubMed ID: 19566821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The myocardial protective effects of puerarin on STZ-induced diabetic rats.
    Pan ZY; Bao ZS; Wu ZM; Wang XM; Zheng JZ; Shen YL; Zhang XM
    Fen Zi Xi Bao Sheng Wu Xue Bao; 2009 Apr; 42(2):137-44. PubMed ID: 19537197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
    Setti G; Hayward A; Dessapt C; Barone F; Buckingham R; White K; Bilous R; Hiroshi K; Gruden G; Viberti G; Gnudi L
    Am J Nephrol; 2010; 32(5):393-402. PubMed ID: 20814199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E; Stocker C; Augstein P; Heinke P; Meyer A; Hoffmann T; Subramanian A; Sennitt MV; Demuth HU; Arch JR; Cawthorne MA
    Diabetes Obes Metab; 2005 Mar; 7(2):170-81. PubMed ID: 15715890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of hypoglycemic activity of Subetta and rosiglitazone on the model of streptozotocin-induced diabetes mellitus in rats.
    Kheyfets IA; Spasov AA; Voronkova MP; Dugina JL; Epstein OI
    Bull Exp Biol Med; 2012 May; 153(1):54-6. PubMed ID: 22808493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.